The active component of Sorafenib is found in Sorafenat (Sorafenib) Tablets, which are used to treat specific cancers. Sorafenib is a multikinase inhibitor that specifically targets proteins involved in angiogenesis (the process of blood vessel development) and the proliferation of cancer cells. Advanced renal cell carcinoma (kidney cancer), unresectable hepatocellular carcinoma (liver cancer), and a few forms of thyroid cancer are the main conditions for which these tablets are prescribed. Sorafenib reduces the growth and spread of cancer cells, which shrinks tumours and increases patient survival. Patients can conveniently take sorafenat by mouth. For the management of probable side effects and to maximise therapeutic benefits, regular medical monitoring is crucial during therapy.
1. Advanced Renal Cell Carcinoma (RCC): Sorafenat is prescribed to treat RCC, a kind of kidney cancer that has metastasized outside of the kidney.
2. Unresectable Hepatocellular Carcinoma (HCC): It is used to treat the most prevalent form of liver cancer, unresectable hepatocellular carcinoma.
3. Differentiated Thyroid Carcinoma: Sorafenat is recommended in some thyroid cancer cases, especially for differentiated thyroid carcinoma that has spread locally or distantly.
The main component of Sorafenat is Sorafenib, a multikinase inhibitor that specifically targets proteins involved in angiogenesis and the development of cancer cells. Sorafenat helps to slow down the growth and spread of cancer cells by blocking these pathways, which results in tumour reduction and better patient outcomes.